An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Pharmaceutical giant Novo Nordisk says an oral version of semaglutide — the active ingredient in blockbuster drugs Ozempic ...

Two major clinical trials evaluating the potential of the weight-loss drug semaglutide to treat Alzheimer’s disease have ...

Novo Nordisk's blockbuster weight loss drug semaglutide failed to slow Alzheimer's progression in trials. The studies had ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular ...

Novo Nordisk shares plunge after its oral semaglutide Alzheimer’s trials fail, raising fresh doubts over its push into a ...

Novo Nordisk presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The ...

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though ...